Riskpilot← Back to searchSign inGet full accessMedapta Oy
OYActiveY-tunnus 2509259-7Valimotie 7Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20120 employees
Revenue 2025
EUR 7,2M
-13% vs 2024
EBITDA margin
14.6%
+26% vs 2024
Equity ratio
81.8%
Financial strength
Net profit 2025
EUR 26
-95% vs 2024
| Revenue | EUR 7,2M | -13% |
| EBITDA | EUR 1M | +26% |
| Net profit | EUR 26 | -95% |
| Total assets | EUR 1,7M | +2% |
| Equity | EUR 1,4M | +0% |
| Employees | 0 | — |
Legal name
Medapta Oy
Y-tunnus number
2509259-7
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2. marraskuuta 2012
Share capital
EUR 2 500
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsen ja toimitusjohtaja yhdessä sekä hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on lääkkeiden tukkukauppa, terveydenhuollon laitteiden ja tarvikkeiden maahantuonti ja myynti, lääkkeiden annosjakelu sekä apteekkipalvelujen tuottaminen ja myynti.
Address
Valimotie 7
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 452 | 3 689 | 4 247 | 6 783 | 9 013 | −7 220 | 8 300 | 7 181 |
| Staff expenses | — | — | — | — | — | −0 | −0 | −0 |
| EBITDA | 233 | 389 | 384 | 640 | 894 | 925 | 831 | 1 049 |
| Depreciation & amort. | −1 | −1 | −1 | −1 | — | −0 | −0 | −0 |
| EBIT | 231 | 388 | 383 | 638 | 894 | 925 | 831 | 1 049 |
| Net financials | — | — | — | −4 | 3 | 54 | 54 | 21 |
| Profit before tax | 231 | 388 | 383 | 130 | 181 | 1 | 1 | 0 |
| Tax | 47 | 78 | 76 | 127 | 179 | 0 | 0 | 0 |
| Net profit | 185 | 310 | 307 | 3 | 2 | 1 | 1 | 0 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 834 | 1 173 | 1 704 | 2 303 | 2 543 | 1 757 | 1 658 | 1 685 |
| Equity | 756 | 1 066 | 1 373 | 1 376 | 1 378 | 1 378 | 1 379 | 1 379 |
| Long-term debt | 0 | — | — | 0 | — | 0 | 0 | 0 |
| Short-term debt | 78 | 106 | 333 | 927 | 1 165 | 378 | 279 | 306 |
| Total debt | 78 | 106 | 333 | 927 | 1 165 | 378 | 279 | 306 |
EBITDA margin
14.6%
This company
15.8%
Market median
-8% vs market
20182025
Equity ratio
81.8%
This company
38.2%
Market median
+114% vs market
20182025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20182025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20182025
Asset turnover
4.26×
This company
1.12×
Market median
+280% vs market
20182025
Debt / equity
0.22×
This company
0.62×
Market median
+65% vs market
20182025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via PRH / YTJ · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
II Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
LT | Audit | 2014 | — | — |
PJ Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
IJ Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
TT Audit | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairperson | 2018 | — | — | |
| Chairperson | 2019 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medapta Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Inka Ilona Puumalainen | Chief Executive Officer | 0 companies |
| Lauri Tuomas Honkamäki | Audit | 0 companies |
| Pekka Juha Tapani Koivuneva | Chief Executive Officer | 0 companies |
| Ilari Juhana Vaalavirta | Chief Executive Officer | 0 companies |
| Tomi Tapani Moisio | Audit | 0 companies |
| Anu Maarit Littunen | Board of Directors | 0 companies |
| Minna Helena Laikka | Board of Directors | 0 companies |
| Jenni Milla Jemiina Tyrni | Board of Directors | 0 companies |
| Annastiina Palmroth-Holst | Board of Directors | 0 companies |
| Ari Jukka Niemi | Chairperson | 0 companies |
| Kimmo Sakari Virtanen | Chairperson | 0 companies |
| Laura Kristiina Ahonen | Board of Directors | 0 companies |